Decitabine limits escape from MEK inhibition in uveal melanoma
Pigment cell & melanoma research, 2019.
MEK inhibitors (MEKi) demonstrate anti-proliferative activity in patients with metastatic uveal melanoma, but responses are short-lived. In the present study, we evaluated the MEKi trametinib alone and in combination with drugs targeting epigenetic regulators, including DOT1L, EZH2, LSD1, DNA methyltransferases and histone acetyltransfera...More
Full Text (Upload PDF)
PPT (Upload PPT)